Holen Sie sich die Stockscreener-App
2.43
0.41%
-0.010
Vorhandelsmarkt:
2.39
-0.04
-1.65%
Schlusskurs vom Vortag:
$2.44
Offen:
$2.44
24-Stunden-Volumen:
1.43M
Relative Volume:
1.05
Marktkapitalisierung:
$223.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.15M
KGV:
-2.6703
EPS:
-0.91
Netto-Cashflow:
$-31.63M
1W Leistung:
+7.52%
1M Leistung:
+63.09%
6M Leistung:
+257.35%
1J Leistung:
+203.75%
1-Tages-Spanne:
$2.40
$2.58
1-Wochen-Bereich:
$2.02
$2.58
52-Wochen-Spanne:
$0.49
$2.85
Context Therapeutics Inc Stock (CNTX) Company Profile
Firmenname
Context Therapeutics Inc
Sektor
Branche
Telefon
267-225-7416
Adresse
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
2.43 | 224.19M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-11-25 | Eingeleitet | D. Boral Capital | Buy |
| 2024-05-16 | Eingeleitet | Piper Sandler | Overweight |
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
ALNA Allena Pharmaceuticals NASDAQ Intraday 12 Feb 2026: Volume up at $0.075 - Meyka
Context Therapeutics to Participate in Upcoming Investor Conferences - The Globe and Mail
SYNI stock: Synvista Therapeutics (PNK) $0.000001 on 10 Feb 2026, oversold bounce - Meyka
Context Therapeutics (NASDAQ:CNTX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Market Wrap: Is PARR forming a breakout pattern2025 Market Sentiment & Stepwise Trade Signal Guides - baoquankhu1.vn
Oppenheimer initiates Whitehawk Therapeutics (WHWK) with Outperform Feb 2026 - Meyka
ALNA Allena Pharma NASDAQ Pre-Mkt 06 Feb 2026: Vol 252.31M watch catalyst - Meyka
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Savers Value Village, Inc. (NYSE:SVV) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Aug Spikes: What is Context Therapeutics Incs book value per share2025 Sector Review & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation - Yahoo Finance
THCT stock rises 4,650% to $0.019 on PNK: short-term volume spike flags high volatility - Meyka
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Sahm
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Madrigal Grants Equity to 40 New Hires as MASH Drug Push Accelerates - MyChesCo
TELA Bio Grants Equity to New Hires as Medtech Growth Push Continues - mychesco.com
Madrigal Taps New Accounting Chief With Six-Figure Equity Bet - mychesco.com
Savara Grants Equity Awards to New Hires as It Advances Rare Lung Drug - MyChesCo
Ideas Watch: How does Context Therapeutics Inc compare to its peersWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
How does Context Therapeutics Inc compare to its peersWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Context Therapeutics Insiders May Regret Not Buying More, Market Cap Hits US$151m - Sahm
JonesTrading Sticks to Its Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail
Sarepta Therapeutics, Inc. (SRPT) stock: surges after-hours ahead of key Phase 3 results webcast - parameter.io
Bell Rings on Wall Street as Medicus Marks One Year as Nasdaq Player - mychesco.com
AI Stocks: Can TRTX deliver consistent dividendsJuly 2025 Institutional & Entry Point Confirmation Signals - baoquankhu1.vn
Context Therapeutics (NASDAQ: CNTX) Issues Equity Awards to Attract New Talent - MyChesCo
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY) - The Globe and Mail
Aug PostEarnings: Is Context Therapeutics Inc. likely to announce a buyback2025 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Sandoz Group (OTCMKTS:SDZNY) versus Context Therapeutics (NASDAQ:CNTX) Head-To-Head Contrast - Defense World
emerging us stocks2025 Price Targets & Verified Technical Trade Signals - Bollywood Helpline
Ideas Watch: How does Context Therapeutics Inc perform in inflationary periodsMarket Trend Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
HER2-Negative Metastatic Breast Cancer Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai - Barchart.com
Contineum Therapeutics Reports Phase 2 Trial Results - MSN
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
DFTX Stock Price, News & Analysis - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Travere Therapeutics (TVTX) - The Globe and Mail
CEO Moves: Can Context Therapeutics Inc. stock double in the next year2025 Market Sentiment & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Revenue Check: Does Consensus Cloud Solutions Inc stock trade at a discount to peers2025 Volume Leaders & Stock Timing and Entry Methods - Bộ Nội Vụ
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board - MSN
Will Context Therapeutics Inc. stock benefit from automationPortfolio Gains Summary & Risk Adjusted Swing Trade Ideas - Улправда
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care - MyChesCo
Context Therapeutics Inc.Common Stock (NQ: CNTX - FinancialContent
User | inyoregister.comContext Therapeutics Inc.Common Stock (Nasdaq:CNTX) Stock Quote - FinancialContent
Pasadena Star News - FinancialContent
Moving Average Crossover Confirms Uptrend in Manugraph India LimitedFederal Reserve Announcements & Breakout Portfolio Performance - bollywoodhelpline.com
About Us - FinancialContent
Can Context Therapeutics Inc. stock hit record highs againWeekly Earnings Recap & Weekly Top Stock Performers List - Улправда
Will Theranexus Société Anonyme (3VG) stock beat value stocks2025 Big Picture & Proven Capital Preservation Methods - ulpravda.ru
Finanzdaten der Context Therapeutics Inc-Aktie (CNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Context Therapeutics Inc-Aktie (CNTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):